Glaxo to Settle Relafen Suit for $75 Million
From Bloomberg News
GlaxoSmithKline agreed to pay $75 million to settle a lawsuit filed by consumers and insurers that said the company illegally blocked a generic form of the arthritis drug Relafen.
The accord was reached with consumers and health insurers, including union health funds, according to Prescription Access Litigation, which sues drug makers over pricing matters. In February, Brentford, England-based Glaxo agreed to pay $175 million to settle a related suit by direct purchasers.
The settlement must be approved by a federal judge in Boston.
